Sinusoidal obstruction syndrome (SOS) related to chemotherapy for colorectal liver metastases: Factors predictive of severe SOS lesions and protective effect of bevacizumab

HPB

Volumn 15, Issue 11, 2013, Pages 858-864

  Hubert, Catherine ^a   Sempoux, Christine ^a   Humblet, Yves ^a   Van Den Eynde, Marc ^a   Zech, Francis ^a   Leclercq, Isabelle ^a   Gigot, Jean François ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BEVACIZUMAB; BILIRUBIN GLUCURONIDE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; GAMMA GLUTAMYLTRANSFERASE; IRINOTECAN; OXALIPLATIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ARTIFICIAL EMBOLISM; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CLINICAL FEATURE; COLORECTAL LIVER METASTASIS; DISEASE SEVERITY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; LIVER FUNCTION; LIVER PARENCHYMA; LIVER RESECTION; LIVER SURGERY; LIVER VENOOCCLUSIVE DISEASE; LIVER WEIGHT; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PORTAL HYPERTENSION; RETROSPECTIVE STUDY; SPLENOMEGALY; THROMBOCYTE; THROMBOCYTE COUNT; ADOLESCENT; BLOOD; CHEMICALLY INDUCED; COLORECTAL NEOPLASMS; COMPLICATION; FOLLOW UP; HEPATIC VENO-OCCLUSIVE DISEASE; LIVER NEOPLASMS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SECONDARY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; ASPARTATE AMINOTRANSFERASES; BEVACIZUMAB; BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SPLENOMEGALY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84886085398     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/hpb.12047     Document Type: Article

References (34)

1. Adam R,. (2007) Colorectal cancer with synchronous liver metastases. Br J Surg 94: 129-131.
2. Nordlinger B, Van CE, Rougier P, Kohne CH, Ychou M, Sobrero A, et al. (2007) Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Eur J Cancer 43: 2037-2045.
3. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomized controlled trial. Lancet 371: 1007-1016.
4. Ribero D, Wang H, Donadon M, Zorzi D, Thomas MB, Eng C, et al. (2007) Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 110: 2761-2767.
5. Van CE, Nordlinger B, Adam R, Kohne CH, Pozzo C, Poston G, et al. (2006) Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 42: 2212-2221.
6. Gruenberger B, Scheithauer W, Punzengruber R, Zielinski C, Tamandl D, Gruenberger T,. (2008) Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases. BMC Cancer 8: 120.
7. Adam R, Pascal G, Castaing D, Azoulay D, Delvart V, Paule B, et al. (2004) Tumour progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg 240: 1052-1061.
8. Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le CM, et al. (2004) Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 15: 460-466.
9. Hubert C, Sempoux C, Horsmans Y, Rahier J, Humblet Y, Machiels JP, et al. (2007) Nodular regenerative hyperplasia: a deleterious consequence of chemotherapy for colorectal liver metastases? Liver Int 27: 938-943.
10. Hubert C, Fervaille C, Sempoux C, Horsmans Y, Humblet Y, Machiels JP, et al. (2010) Prevalence and clinical relevance of pathological hepatic changes occurring after neoadjuvant chemotherapy for colorectal liver metastases. Surgery 147: 185-194.
11. Karoui M, Penna C, Min-Hashem M, Mitry E, Benoist S, Franc B, et al. (2006) Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 243: 1-7.
12. Nakano H, Oussoultzoglou E, Rosso E, Casnedi S, Chenard-Neu MP, Dufour P, et al. (2008) Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg 247: 118-124.
13. Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, et al. (2006) Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24: 2065-2072.
14. Chun YS, Laurent A, Maru D, Vauthey JN,. (2009) Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases. Lancet Oncol 10: 278-286.
15. Zorzi D, Laurent A, Pawlik TM, Lauwers GY, Vauthey JN, Abdalla EK,. (2007) Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 94: 274-286.
16. Wicherts DA, de Haas RJ, Sebagh M, Ciacio O, Levi F, Paule B, et al. (2011) Regenerative nodular hyperplasia of the liver related to chemotherapy: impact on outcome of liver surgery for colorectal metastases. Ann Surg Oncol 18: 659-669.
17. Taylor AJ, Dodds WJ, Erickson SJ, Stewart ET,. (1991) CT of acquired abnormalities of the spleen. AJR Am J Roentgenol 157: 1213-1219.
18. Hemming AW, Scudamore CH, Shackleton CR, Pudek M, Erb SR,. (1992) Indocyanine green clearance as a predictor of successful hepatic resection in cirrhotic patients. Am J Surg 163: 515-518.
19. Leevy CM, Smith F, Longueville J, Paumgartner G, Howard MM,. (1967) Indocyanine green clearance as a test for hepatic function. Evaluation by dichromatic ear densitometry. JAMA 200: 236-240.
20. Koda M, Matunaga Y, Kawakami M, Kishimoto Y, Suou T, Murawaki Y,. (2007) FibroIndex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. Hepatology 45: 297-306.
21. Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, et al. (2007) FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology 46: 32-36.
22. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. (2003) A simple non-invasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 38: 518-526.
23. Snell EJ,. (1964) A scaling procedure for ordered categorical data. Biometrics 20: 592-607.
24. Aloia T, Sebagh M, Plasse M, Karam V, Levi F, Giacchetti S, et al. (2006) Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 24: 4983-4990.
25. Mehta NN, Ravikumar R, Coldham CA, Buckels JA, Hubscher SG, Bramhall SR, et al. (2008) Effect of preoperative chemotherapy on liver resection for colorectal liver metastases. Eur J Surg Oncol 34: 782-786.
26. Soubrane O, Brouquet A, Zalinski S, Terris B, Brezault C, Mallet V, et al. (2010) Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome. Ann Surg 251: 454-460.
27. Abulkhir A, Limongelli P, Healey AJ, Damrah O, Tait P, Jackson J, et al. (2008) Preoperative portal vein embolization for major liver resection: a meta-analysis. Ann Surg 247: 49-57.
28. Hemming AW, Reed AI, Howard RJ, Fujita S, Hochwald SN, Caridi JG, et al. (2003) Preoperative portal vein embolization for extended hepatectomy. Ann Surg 237: 686-691.
29. Rubbia-Brandt L, Lauwers GY, Wang H, Majno PE, Tanabe K, Zhu AX, et al. (2010) Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology 56: 430-439.
30. Overman MJ, Maru DM, Charnsangavej C, Loyer EM, Wang H, Pathak P, et al. (2010) Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. J Clin Oncol 28: 2549-2555.
31. Kesmodel SB, Ellis LM, Lin E, Chang GJ, Abdalla EK, Kopetz S, et al. (2008) Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol 26: 5254-5260.
32. D'Angelica M, Kornprat P, Gonen M, Chung KY, Jarnagin WR, DeMatteo RP, et al. (2007) Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study. Ann Surg Oncol 14: 759-765.
33. Reddy SK, Morse MA, Hurwitz HI, Bendell JC, Gan TJ, Hill SE, et al. (2008) Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 206: 96-106.
34. Klinger M, Eipeldauer S, Hacker S, Herberger B, Tamandl D, Dorfmeister M, et al. (2009) Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. Eur J Surg Oncol 35: 515-520.